We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Renal failure

14 Dec 2021 By Jeffrey Goldfarb

The Australian flu-vaccine maker will buy Swiss nephrology specialist Vifor for about $12 bln in cash. It’s paying a 60% premium for a weaker peer and doesn’t expect much in the way of cost savings. The mid-pandemic diversification hardly justifies this elective M&A procedure.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)